David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
According to O’Malley, there is a growing group of patients who are not eligible to platinum therapy due to either hypersensitive or treatment with the agent in the past. These patients are often no longer eligible for clinical trials.
When looking at this population group, the overall historical experience of this group is limited. This means that data on this population is equally limited, according to O’Malley. Patients who are platinum-agnostic are often treated with non-platinum containing agents, such as bevacizumab (Avastin).
FDA Fast Tracks Lunresertib/Camonsertib in Platinum-Resistant Ovarian Cancer
June 6th 2024The FDA granted fast track status to lunresertib and camonsertib for platinum-resistant ovarian cancer with specific mutations, currently being evaluated for safety and efficacy in the phase 1 MYTHIC trial, with results expected in late 2024.
Read More